UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 30, 2008

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, a non-accelerated filer or a smaller

reporting company. See definitions of "large accelerated filer," "accelerated

filer" and "smaller reporting company" in Rule 12b-2 of the

Exchange Act (Check one):

Large accelerated filer X Accelerated

filer Non-accelerated

filer Smaller

reporting company

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At April 30, 2008, 6,765,196,985 shares of the issuer's

voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

March 30, 2008

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months ended March 30, 2008,

and April 1, 2007

Condensed

Consolidated Balance Sheets as of March 30, 2008, and December 31, 2007

Condensed

Consolidated Statements of Cash Flows for the three months ended March 30,

2008, and April 1, 2007

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

16

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

43

Item 4.

Controls and

Procedures

43

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

43

Item 1A.

Risk Factors

46

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

47

Item 3.

Defaults Upon

Senior Securities

47

Item 4.

Submission of

Matters to a Vote of Security Holders

48

Item 5.

Other

Information

48

Item 6.

Exhibits

49

Signature

50

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three

Months Ended

(millions, except per common share

data)

Mar. 30,

2008

April 1,

2007

Revenues

11,848

12,474

Costs and expenses:

Cost of sales(a)

1,986

1,887

Selling,

informational and administrative expenses(a)

3,492

3,361

Research and

development expenses(a)

1,791

1,665

Amortization of

intangible assets

779

815

Acquisition-related

in-process research and development charges

398

283

Restructuring

charges and acquisition-related costs

178

812

Other

(income)/deductions - net

(333)

(402)

Income from

continuing operations before provision for taxes on income and minority

interests

3,557

4,053

Provision for

taxes on income

763

689

Minority

interests

Income from

continuing operations

2,788

3,361

Discontinued

operations:

Loss from

discontinued operations - net of tax

(4)

--

Gains on sales

of discontinued operations - net of tax

--

31

Discontinued

operations - net of tax

(4)

31

Net income

2,784

3,392

Earnings per common share - basic:

Income from

continuing operations

0.41

0.48

Discontinued

operations - net of tax

--

--

Net income

0.41

0.48

Earnings per common share -

diluted:

Income from

continuing operations

0.41

0.48

Discontinued

operations - net of tax

--

--

Net income

0.41

0.48

Weighted-average

shares used to calculate earnings per common share:

Basic

6,739

7,051

Diluted

6,762

7,075

Cash dividends paid per common

share

0.32

0.29

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 8B. Goodwill and Other

Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

Mar. 30,

2008*

Dec. 31,

2007**

ASSETS

Cash and cash equivalents

2,013

3,406

Short-term investments

26,615

22,069

Accounts receivable, less allowance

for doubtful accounts

10,432

9,843

Short-term loans

777

617

Inventories

5,148

5,302

Prepaid expenses and taxes

5,939

5,498

Assets held for sale

87

114

Total current assets

51,011

46,849

Long-term

investments and loans

4,511

4,856

Property, plant and equipment, less

accumulated depreciation

15,383

15,734

Goodwill

21,556

21,382

Identifiable

intangible assets, less accumulated amortization

19,896

20,498

Other assets,

deferred taxes and deferred charges

6,193

5,949

Total assets

118,550

115,268

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

8,909

5,825

Accounts payable

1,909

2,270

Dividends payable

2,163

Income taxes payable

1,221

1,380

Accrued compensation and related

items

1,622

1,974

Other current liabilities

8,020

8,223

Total current liabilities

21,682

21,835

Long-term debt

8,143

7,314

Pension benefit

obligations

2,550

2,599

Postretirement

benefit obligations

1,703

1,708

Deferred taxes

7,441

7,696

Other taxes

payable

6,284

6,246

Other

noncurrent liabilities

3,187

2,746

Total liabilities

50,990

50,144

Minority interests

143

114

Preferred stock

86

93

Common stock

443

442

Additional

paid-in capital

70,001

69,913

Employee

benefit trust, at fair value

(459)

(550)

Treasury stock

(56,883)

(56,847)

Retained

earnings

52,436

49,660

Accumulated

other comprehensive income

1,793

2,299

Total shareholders' equity

67,417

65,010

Total liabilities and shareholders'

equity

118,550

115,268

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three

Months Ended

(millions of dollars)

Mar. 30,

2008

April 1,

2007

Operating

Activities:

Net income

2,784

3,392

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

1,487

1,271

Share-based

compensation expense

101

141

Acquisition-related

in-process research and development charges

398

283

Gains on

disposals

(23)

(7)

Gains on sales

of discontinued operations

--

(40)

Deferred taxes

from continuing operations

544

(268)

Other non-cash

adjustments

242

58

Changes in

assets and liabilities (net of businesses acquired and divested)

(2,262)

(3,587)

Net cash provided by operating

activities

3,271

1,243

Investing Activities:

Purchases of

property, plant and equipment

(483)

(329)

Purchases of

short-term investments

(10,648)

(5,617)

Proceeds from sales

and redemptions of short-term investments

6,817

11,819

Purchases of long-term

investments

(498)

(1,158)

Proceeds from sales

and redemptions of long-term investments

42

Purchases of

other assets

(14)

(2)

Proceeds from

the sales of businesses, products and product lines

--

Acquisitions,

net of cash acquired

(610)

(463)

Other investing

activities

(90)

Net cash (used in)/provided by

investing activities

(5,484)

4,271

Financing Activities:

Increase in

short-term borrowings, net

4,899

162

Principal

payments on short-term borrowings

(1,955)

(729)

Proceeds from

issuances of long-term debt

602

19

Principal

payments on long-term debt

(561)

(58)

Purchases of

common stock

--

(2,500)

Cash dividends

paid

(2,138)

(2,032)

Stock option

transactions and other

290

Net cash provided

by/(used in) financing activities

848

(4,848)

Effect of

exchange-rate changes on cash and cash equivalents

(28)

(1)

Net (decrease)/increase

in cash and cash equivalents

(1,393)

665

Cash and cash

equivalents at beginning of period

3,406

1,827

Cash and cash

equivalents at end of period

2,013

2,492

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

640

2,424

Interest

166

170

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and

operating results for subsidiaries operating outside the U.S. are as of and for

the three-month periods ended February 24, 2008, and February 25, 2007.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2007.

Note 2. Adoption of New

Accounting Policies

As of January 1, 2008, we adopted on

a prospective basis certain required provisions of Statement of Financial

Accounting Standards (SFAS) No. 157, Fair Value Measurements, as amended

by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157-2,

Effective Date of FASB Statement No. 157. Those provisions relate to our

financial assets and liabilities carried at fair value and our fair value

disclosures related to financial assets and liabilities. SFAS 157 defines fair

value, expands related disclosure requirements and specifies a hierarchy of

valuation techniques based on the nature of the inputs used to develop the fair

value measures. Fair value is defined as the price that would be received to

sell an asset or paid to transfer a liability in an orderly transaction between

market participants at the measurement date. There are three levels of inputs

to fair value measurements - Level 1, meaning the use of quoted prices for

identical instruments in active markets; Level 2, meaning the use of quoted

prices for similar instruments in active markets or quoted prices for identical

or similar instruments in markets that are not active or are directly or

indirectly observable; and Level 3, meaning the use of unobservable inputs.

Observable market data should be used when available.

Many, but not all, of our financial

instruments are carried at fair value. For example,

substantially all of our cash equivalents, short-term investments and long-term

investments are classified as available-for-sale securities and are carried at

fair value, with unrealized gains and losses, net of tax, reported in Other

comprehensive income. Derivative financial instruments are carried

at fair value, with changes in fair value reported in various balance sheet

categories (see both Note 10 D. Financial Instruments: Derivative Financial

Instruments and Hedging Activities in our 2007 Annual Report, and Note 6C.

Financial Instruments: Derivative Financial Instruments and Hedging Activities in

this Quarterly Report) and ultimately, in Other (income)/deductions - net.

Virtually all of our valuation measurements are Level 2 measurements. The

adoption of SFAS 157 did not have a significant impact on our consolidated financial

statements. We did not elect to adopt SFAS 157 for acquired non-financial

assets and assumed non-financial liabilities.

Emerging Issues Task Force (EITF)

Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or

Services to Be Used in Future Research and Development Activities, became

effective for new contracts entered into on or after January 1, 2008. EITF

Issue No. 07-3 requires that non-refundable advance payments for goods and

services that will be used in future research and development (R&D)

activities be expensed when the R&D activity has been performed or

when the R&D goods have been received rather than when the payment is made.

The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated

financial statements.

Note 3. Acquisitions

During the first quarters of 2008 and

2007, we acquired the following:

In January 2008, we acquired CovX,

a privately held biotherapeutics company specializing in preclinical oncology

and metabolic research and the developer of a biotherapeutics technology platform

that we expect will enhance our biologic portfolio. Also in January 2008, we

acquired all the outstanding shares of Coley Pharmaceutical Group, Inc., a

biopharmaceutical company specializing in vaccines and drug candidates

designed to fight cancers, allergy and asthma disorders, and autoimmune

diseases, for approximately $230 million. In connection with these and two

smaller acquisitions related to Animal Health, we recorded $398 million in Acquisition-related

in-process research and development charges.

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a number of diabetes candidates and a novel technology platform

for developing new protein drug candidates, and Embrex, Inc., an animal

health company that possesses a unique vaccine delivery system known as

Inovoject that improves consistency and reliability by inoculating chicks

while they are still inside the egg. In connection with these and other small

acquisitions, we recorded $283 million in Acquisition-related

in-process research and development charges.

Note 4. Cost-Reduction

Initiatives

We incurred the following costs in

connection with our cost-reduction initiatives.

First

Quarter

(millions

of dollars)

Mar. 30,

2008

April 1,

2007

Implementation

costs(a)

357

174

Restructuring

charges(b)

177

795

Total costs

related to our cost-reduction initiatives

534

969

(a)

For

the first quarter of 2008, included in Cost of sales ($138 million),

Selling, informational and administrative expenses ($75 million), Research

and development expenses ($146 million), and Other (income)/deductions-net

($2 million income). For the first quarter of 2007, included in Cost of

sales ($94 million), Selling, informational and administrative

expenses ($49 million), and Research and development expenses

($31 million).

(b)

Included

in Restructuring charges and acquisition-related costs.

Through March 30, 2008, the

restructuring charges primarily relate to our plant network optimization

efforts and the restructuring of our U.S. marketing and worldwide research and

development operations, while the implementation costs primarily relate to accelerated

depreciation of certain assets, as well as system and process standardization

and the expansion of shared services.

The components of restructuring charges

associated with our cost-reduction initiatives follow:

(millions

of dollars)

Costs

Incurred

Through

Mar. 30,

2008

Activity

Through

Mar. 30,

2008

(a)

Accrual

as of

Mar. 30,

2008

(b)

Employee

termination costs

3,272

2,288

984

Asset

impairments

784

784

--

Other

378

278

100

Total

4,434

3,350

1,084

(a)

Includes

adjustments for foreign currency translation.

(b)

Included

in Other current liabilities ($958 million) and Other

noncurrent liabilities ($126 million).

During the first quarter of 2008, we

expensed $126 million for Employee termination costs, $34 million

for Asset impairments and $17 million in Other. Through March 30,

2008, Employee termination costs represent the expected reduction

of the workforce by 21,200 employees, mainly in manufacturing, sales and

research. Approximately 13,700 employees were terminated as of March 30,

2008. Employee termination costs include accrued severance benefits,

pension and postretirement benefits. Asset impairments primarily include

charges to write down property, plant and equipment. Other primarily

includes costs to exit certain activities.

Note 5. Comprehensive

Income

The components of comprehensive

income/(expense) follow:

First

Quarter

(millions of dollars)

Mar.

30, 2008

April

1, 2007

Net income

2,784

3,392

Other comprehensive

income/(expense):

Currency

translation adjustment and other

(577)

(128)

Net unrealized

gains/(losses) on derivative financial instruments

Net unrealized

gains/(losses) on available-for-sale securities

(14)

(4)

Benefit plan

adjustments

84

81

Total other

comprehensive income/(expense)

(506)

(42)

Total comprehensive income

2,278

3,350

Note 6. Financial

Instruments

A. Financial

Instruments

As of January 1, 2008, we adopted on

a prospective basis certain required provisions of SFAS 157, as amended by FSP

157-2. (See Note 2. Adoption of New Accounting Policies).

Information about certain of our

financial assets and liabilities follows:

Fair

Value(a)

(millions

of dollars)

As of

Mar. 30,

2008

Level 1

Level 2

Level 3

Financial assets carried at fair

value:

Trading securities(b)

213

--

213

--

Available-for-sale debt securities(c)

27,360

--

27,360

--

Available-for-sale equity

securities(d)

1,665

265

1,400

--

Derivative financial instruments(e)

866